Award of NHS National Pharmaceuticals Framework for Everolimus and Terminated Agreement Products

About

NHS England awarded a contract to Selective Supplies Ltd., Dr.Reddy's Laboratories (UK) Limited, Bristol Laboratories Limited, Drugsrus Ltd, Bowmed Ibisqus Limited, Martindale Pharma, Milpharm Ltd/aurobinbdo, Teva UK Limited, and Crescent Pharma for the supply of Everolimus and terminated agreement products under the NHS National Pharmaceuticals framework.

The framework agreement includes an option to extend up to a total of 24 months, with call-offs for Everolimus across all regions ending 01/03/2022, Oral Products across all regions ending 28/02/2022, and Hospital Only Products in the DLS, DNE, DNW, DLN, and DSW regions ending 31/01/2022.

The contract value is £4,516,089.